Atopic Dermatitis

Contrary to short-term phase 3 research, the JAK-1 inhibitor was not dose-dependent nor less effective in older adult patients over nearly 2 years.

Siegfried spoke on the subjects covered in her presentation at the Revolutionizing Atopic Dermatitis conference, specifically the different conditions that can mirror eczema in infancy.

In her presentation at the Revolutionizing Atopic Dermatitis conference, Melinda Gooderham spoke about 4 specific upcoming therapies set to arrive this year for patients with eczema, including 2 nonsteroidal topicals.

In this interview, King discussed his Revolutionizing Atopic Dermatitis presentation on his views about the safety of JAK inhibitors in otherwise healthy eczema patients.

Diamant Thaci, MD, reviewed the state of real-world biologic therapy use for moderate to severe atopic dermatitis during a session at RAD 2023.

During another interview segment, Silverberg highlighted some new insights into oral JAK-inhibitors from his presentation at the Revolutionizing Atopic Dermatitis conference.

In this interview segment, Silverberg discussed some of the major takeaways from his Revolutionizing Atopic Dermatitis presentation on eligibility for systemic treatments.

An open-label extension trial shows dupilumab provides similar skin clearance and itch benefit at 5 years as it had at 1 year of treatment.

Interim analysis suggest the JAK inhibitor may become a breakthrough treatment for chronic hand dermatitis—a condition currently without a marketed drug.

Post-hoc data from the phase 3 ADhere trial shows a lebrikizumab regimen may help patients with atopic dermatitis achieve skin clearance they could not with dupilumab.

Eichenfield discussed the major takeaways from his Revolutionizing Atopic Dermatology conference presentation regarding recent data on PDE4 and JAK inhibitors for eczema patients.

During this interview segment, Singh spoke on the ways in which dermatologists may help infants manage atopic dermatitis, as well as her outlook on the future of treatment.

In this interview, Singh described the major takeaways from her presentation on allergy testing for infants which she gave at the Revolutionizing Atopic Dermatitis conference.

A Brazil cross-sectional analysis suggests chronic pruritus is even more common—and burdensome—in atopic dermatitis patients than previously believed.

Eichenfield discussed his first presentation at the Revolutionizing Atopic Dermatitis conference, with his discussion covering systemic atopic dermatitis treatment for infants.

A new qualitative study of adults with atopic dermatitis shows preference for skin clearance, reduced risk of severe adverse events and a less frequent dosage.

New data show the novel investigative drug from Amytrx was associated with 37% improvement in atopic dermatitis body surface area.

Updated analysis of more than a dozen clinical trials assessing monotherapy systemic treatment of atopic dermatitis shows upadacitinib's highly prevalent efficacy in clearing skin.

Experts in dermatology consider the use of the Atopic Dermatitis Control Tool and other tools to assess severity of atopic dermatitis.

Aaron S. Farberg, MD, discusses how new therapies have impacted his approach to treatment of atopic dermatitis.

Key opinion leaders navigate diagnostic challenges associated with atopic dermatitis.

Casey Butrus, PharmD, leads a panel of experts in a discussion surrounding atopic dermatitis.

Alexandra Golant, MD, comments on the adverse events of systemic therapies and how emerging nonsteroidal agents have a better safety profile in atopic dermatitis.

Matthew Zirwas, MD, highlights therapies that are available for the treatment of atopic dermatitis, including corticosteroids, calcineurin inhibitors and JAK inhibitors.

New results of the phase 3 ECZTRA 6 trial, evaluating tralokinumab for pediatric patients with eczema, found that the drug was superior to placebo in the primary and secondary endpoints.